According to the Zhitong Finance App, Shisi Pharmaceutical Group (02005.HK) announced that the group's laberol hydrochloride has been approved by the China National Drug Administration and registered as an active ingredient for use in marketed formulations. Laberolol hydrochloride is mainly used to treat high blood pressure.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.